MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
MacroGenics, Inc. (MGNX)
Last macrogenics, inc. earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.macrogenics.com
Company Research
Source: GlobeNewswire
Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced three clinical presentations at the American Society of Clinical Oncology (ASCO) upcoming ASCO20 Virtual Scientific Program to be held May 29-31, 2020. ASCO Virtual Presentations Title: A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasmsAuthors: Jason J. Luke, et al.Session: Developmental Therapeutics—ImmunotherapySession Type: Oral Abstract SessionAbstract: 3004 Title: Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumorsAuthors: John D. Powderly, et al.Session: Developmental Therapeutics—Immu
Show less
Read more
Impact Snapshot
Event Time:
MGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGNX alerts
High impacting MacroGenics, Inc. news events
Weekly update
A roundup of the hottest topics
MGNX
News
- MacroGenics (MGNX) had its "overweight" rating reaffirmed by Barclays PLC.MarketBeat
- MacroGenics (MGNX) was upgraded by B. Riley Financial, Inc. from "neutral" to "buy". They now have a $9.00 price target on the stock.MarketBeat
- FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study [Yahoo! Finance]Yahoo! Finance
- FDA Removes Partial Clinical Hold on MacroGenics’ LINNET StudyGlobeNewswire
- MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
MGNX
Earnings
- 11/12/25 - Beat
MGNX
Sec Filings
- 4/8/26 - Form 8-K
- 4/8/26 - Form DEF
- 4/8/26 - Form DEFA14A
- MGNX's page on the SEC website